Pediatric Catheter-related Thrombosis Imaging Study (AESOP)

This study has been completed.
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT01137578
First received: June 3, 2010
Last updated: September 5, 2013
Last verified: September 2013
  Purpose

This protocol will serve as a pilot study to determine the validity and feasibility of contrast enhanced magnetic resonance imaging (MRI) without and with contrast and/or ultrasound (US) for detection of catheter related deep vein thrombosis (DVT) in children


Condition Intervention Phase
Thrombosis
Drug: No Intervention
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Pilot Study for Assessing Diagnostic Techniques for Central Venous Catheter-related Venous Thromboembolism

Resource links provided by NLM:


Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • The number of subjects recruited into the study that are able to undergo each one of the imaging procedures (ultrasound and MRI) that are performed at Visit 1 [ Time Frame: Either at 40±20 days following the placement of the central venous catheter or within 7 days of symptoms of a venous thromboembolism or within 7 days of an incidental diagnosis of CVC-related DVT by radiographic imaging ] [ Designated as safety issue: No ]
    • CVC - Central venous catheter
    • DVT - Deep Vein Thrombosis

    Visit 1, is defined for

    • Cohort A: subjects as day 40 ± 20 days from the placement of the CVC, or if possible within 72 hours after a CVC is removed or lost
    • Cohort B: within 7 days of initiation of symptoms of a CVC-related DVT or within 7 days of an incidental diagnosis of CVC-related DVT by radiographic imaging

  • Frequency and nature of difficulties encountered during each one of the imaging procedures (ultrasound and MRI) that are performed at visit 1 [ Time Frame: Either at 40±20 days following the placement of the central venous catheter or within 7 days of symptoms of a venous thromboembolism or within 7 days of an incidental diagnosis of CVC-related DVT by radiographic imaging ] [ Designated as safety issue: No ]
  • Frequency of subjects with a deep vein thrombosis (DVT) detected by the ultrasound and/or MRI at Visit 1 and confirmed by adjudication [ Time Frame: Either at 40±20 days following the placement of the central venous catheter or within 7 days of symptoms of a venous thromboembolism or within 7 days of an incidental diagnosis of CVC-related DVT by radiographic imaging ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Frequency of subjects in Cohort A asymptomatic for CVC-related DVT identified by the investigator at enrollment and confirmed by at least one adjudicated diagnostic imaging procedure performed at Visit 1 [ Time Frame: Visit 1 is defined for Cohort A subjects as day 40 ± 20 days from the placement of the CVC, or if possible within 72 hours after a CVC is removed or lost ] [ Designated as safety issue: No ]
  • Frequency of symptomatic subjects in Cohort B with CVC-related DVT identified by the investigator at enrollment and confirmed by at least one adjudicated diagnostic imaging procedure performed at Visit 1 [ Time Frame: Visit 1 is defined for Cohort B subjects as within 7 days of initiation of symptoms of a CVC-related DVT or within 7 days of an incidental diagnosis of CVC-related DVT by radiographic imaging ] [ Designated as safety issue: No ]
  • Frequency of subjects in Cohort B with or without symptoms for CVC-related DVT, incidentally identified by radiographic imaging performed for other clinical reasons as having a CVC-related DVT in the veins where the current catheter is placed [ Time Frame: Visit 1 is defined for Cohort B subjects as within 7 days of initiation of symptoms of a CVC-related DVT or within 7 days of an incidental diagnosis of CVC-related DVT by radiographic imaging ] [ Designated as safety issue: No ]
    Frequency of subjects in Cohort B with or without symptoms for CVC-related DVT, who have been incidentally identified by radiographic imaging performed for other clinical reasons as having a CVC-related DVT in the veins where the current catheter is placed, identified by the investigator at enrollment and confirmed by at least one adjudicated diagnostic imaging procedure performed at Visit 1

  • Frequency of asymptomatic subjects enrolled in Cohort A developing symptoms of a VTE, including DVT or Pulmonary embolism (PE), identified by the investigator between enrollment and Visit 1 [ Time Frame: The period between enrollment and Visit 1 is defined for Cohort A subjects as from the time of enrollment up to 60 days after the CVC has been placed, or from the time of enrollment up to 72 hours after the CVC is removed or lost ] [ Designated as safety issue: No ]
    Frequency of asymptomatic subjects enrolled in Cohort A developing symptoms of a Venous thromboembolism (VTE), including DVT or PE, identified by the investigator between enrollment and Visit 1 and confirmed by at least one adjudicated diagnostic imaging procedure performed within 7 days of the initiation of symptoms

  • Frequency of adjudicated PE events (symptomatic or asymptomatic) identified during the course of the study [ Time Frame: From enrollment up to 30 days following the study radiographic procedures (MRI and/or Ultrasound) ] [ Designated as safety issue: No ]
  • Frequency of adjudicated death events occurred during the course of the study [ Time Frame: From enrollment up to 30 days following the study radiographic procedures (MRI and/or Ultrasound) ] [ Designated as safety issue: No ]

Enrollment: 152
Study Start Date: February 2011
Study Completion Date: May 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort A: Asymptomatic
Subjects with a CVC in place and asymptomatic for a CVC-related DVT
Drug: No Intervention
Other Name: Ultrasounds and contrast-enhanced Magnetic Resonance Imaging will be performed on children with central venous catheters
Experimental: Cohort B: Symptomatic or incidental diagnosis
Subjects with a CVC in place either symptomatic for a CVC-related DVT or having an incidental diagnosis of CVC-related DVT by radiographic imaging performed for other clinical reasons
Drug: No Intervention
Other Name: Ultrasounds and contrast-enhanced Magnetic Resonance Imaging will be performed on children with central venous catheters
Experimental: Cohort C: MRI for clinical reasons
Subjects with a CVC in place having an MRI for clinical reasons
Drug: No Intervention
Other Name: Ultrasounds and contrast-enhanced Magnetic Resonance Imaging will be performed on children with central venous catheters

  Eligibility

Ages Eligible for Study:   up to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Functioning central venous catheter in the upper or lower venous system
  • Cohort A: Asymptomatic patients having placement of a new central venous catheter in the last 40±20 days
  • Cohort B: Subjects who have experienced symptoms for a CVC-related DVT with a CVC in place or subjects who have been incidentally identified by radiographic imaging (imaging modalities to diagnose an incidental CVC-related DVT may include, but is not exclusive of Echocardiogram, CT scan, MRI, or Ultrasound) performed for other clinical reasons, as having a CVC-related DVT in the veins where the current catheter is placed
  • Males and females from full-term newborns to < 18 years

Exclusion Criteria:

  • For Cohort A subjects only, present therapeutic dosing of a systematic anticoagulant, systemic thromboprophylaxis or antiplatelet therapy. Local thromboprophylaxis [flushes, low dose infusions of heparin of up to 5 u/kg/hr or locks with heparin, urokinase, t-plasminogen activator] according to standard-of-care at the respective center will be allowed
  • Patients unable to undergo contrast enhanced magnetic resonance imaging
  • Renal function < 50% of normal for age and size
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01137578

  Hide Study Locations
Locations
United States, Arkansas
Arkansas Children'S Hospital
Little Rock, Arkansas, United States, 72202
United States, Colorado
University Of Colorado Denver
Aurora, Colorado, United States, 80045
United States, Missouri
Children'S Mercy Hospital And Clinics
Kansas City, Missouri, United States, 64108-4619
United States, Ohio
Akron Children'S Hospital
Akron, Ohio, United States, 44308
Cincinnati Children'S Hospital Medical Center
Cincinnati, Ohio, United States, 45229-3039
United States, Pennsylvania
The Children'S Hospital Of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
Children'S Hopsital Of Pittsburgh Of Upmc
Pittsburgh, Pennsylvania, United States, 15224
United States, Texas
Dodson Specialty Clinics
Fort Worth, Texas, United States, 76104
Ut Health/Gulf States Hemophilia & Thrombophilia Ctr.
Houston, Texas, United States, 77030
Texas Children'S Hospital
Houston, Texas, United States, 77030
Argentina
Local Institution
Buenos Aires, Argentina, 1270
Local Institution
Buenos Aires, Argentina, 1425
Local Institution
Buenos Aires, Argentina, C1181ACH
Austria
Local Institution
Vienna, Austria, A-1090
Brazil
Local Institution
Sao Paulo, Brazil, 04023-062
Local Institution
Sao Paulo, Brazil, 05410
Canada, Alberta
Local Institution
Edmonton, Alberta, Canada, T6G 1C9
Canada, Ontario
Local Institution
Ottawa, Ontario, Canada, K1H 8L1
Local Institution
Toronto, Ontario, Canada, M5G 1X8
Germany
Local Institution
Freiburg, Germany, 79106
Local Institution
Hannover, Germany, 30625
Mexico
Local Institution
Col. Secc Xvi Tlalpan, Distrito Federal, Mexico, 14080
Local Institution
Guadalajara, Jalisco, Mexico, 44260
Local Institution
Monterrey, Nuevo Leon, Mexico, 64460
Netherlands
Local Institution
Amsterdam, Netherlands, 1105 AZ
United Kingdom
Local Institution
Glasgow, Lanarkshire, United Kingdom, G3 8SJ
Sponsors and Collaborators
Bristol-Myers Squibb
Pfizer
Investigators
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
No publications provided

Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT01137578     History of Changes
Other Study ID Numbers: CV185-077, 2009-016906-18
Study First Received: June 3, 2010
Last Updated: September 5, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Thrombosis
Venous Thromboembolism
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Thromboembolism

ClinicalTrials.gov processed this record on July 22, 2014